Clinical Trials Logo

Allergy clinical trials

View clinical trials related to Allergy.

Filter by:

NCT ID: NCT05918354 Recruiting - Allergy Clinical Trials

Development and Evaluation of an Artificial Intelligence Model for the Diagnosis of Aeroallergies

SPAT_AI
Start date: July 10, 2023
Phase:
Study type: Observational

To improve accuracy and take out human error, Hippo Dx previously developed S.P.A.T., an automated skin prick test. Now, Hippo Dx will develop and evaluate a S.P.A.T. artificial intelligence (AI) medical software to support physicians in the read out of the test results from an automated skin prick test. In this study 700 images will be collected to develop the AI model, an additional 200 images will be collected to evaluate performance of the AI model. In a last independent cohort of 100 patients, performance of read-out by the physician will be compared with read out by the physician supported by the S.P.A.T. AI medical software. The primary endpoint is the accuracy of the maximal wheal size measurement by S.P.A.T. AI versus the maximal wheal size measurement by the physician. It is a prospective multicentric study that will include 1000 study participants from different countries.

NCT ID: NCT05848986 Not yet recruiting - Allergy Clinical Trials

Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet

FERIplaq
Start date: June 1, 2023
Phase:
Study type: Observational

Anaphylactic shock is the most severe expression of immediate hypersensitivity reactions. The mechanisms leading to these reactions are still poorly understood and may involve platelets, especially in the most severe forms. The IgE ( ImmunoglobulineE)-mediated mechanism, involving the FcERI(the high-affinity receptor for the Fc region of immunoglobulin E (IgE) receptor present on the surface of mast cells and basophilic cells, is the most common mechanism. The receptors FcERI and FcERII are also described as being present on the surface of blood platelets, which would imply their activation along with the other cells involved. However, studies showing the presence of the FcERI/RII receptors on blood platelets suffer from many biases. The main objective of the research is to study whether the FcERI/RII receptors are present and functional on the surface of blood platelets from allergic patients.

NCT ID: NCT05810233 Recruiting - Allergy Clinical Trials

Effect of Vitamin C on Allergy Skin Test

Start date: July 15, 2023
Phase: N/A
Study type: Interventional

This study will assess the effect of taking vitamin C on allergy skin test.

NCT ID: NCT05758532 Recruiting - Allergy Clinical Trials

Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children

NEMAU
Start date: March 17, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to evaluate the off-target/non-specific effects of the measles-mumps-rubella (MMR) vaccine in children.

NCT ID: NCT05702671 Completed - Allergy Clinical Trials

Kenota 1 CWS Method Comparison Validation Study

Start date: January 27, 2023
Phase:
Study type: Observational

The goal of this Method Comparison Study is to compare total IgE results obtained from at least 360 subjects aged less than 80 years old using four different testing arms comprising three types of samples and two testing methods. The main questions it aims to answer are: - Are the Kenota 1 Devices easy to use by untrained operators at a clinic environment? - Do tIgE results provided by the Kenota 1 Devices match the results provided by the FDA-cleared Phadia ImmunoCAP System? Subjects will be asked to donate two fingerstick whole blood samples and one venous blood draw.

NCT ID: NCT05698030 Completed - Allergy Clinical Trials

Efficacy and Saffety of Oral Immunotherapy to Pistachio

Start date: January 1, 2020
Phase:
Study type: Observational

The objectives of this study are (i) to evaluate the efficacy of oral immunotherapy to pistachio by evaluating the daily oral tolerance of 2g pistachio, by evaluating the long-term tolerance of 15g pistachio (sustained unresponsiveness) and by decreasing pistachio-specific IgE, (ii) evaluating the efficacy of pistachio immunotherapy on cashew tolerance, (iii) and to evaluate the safety of pistachio immunotherapy.

NCT ID: NCT05637411 Active, not recruiting - Obesity Clinical Trials

GeoHealth: Geographic Information System for Health Management and Clinical, Epidemiological and Translational Research

Start date: December 9, 2020
Phase:
Study type: Observational

The objective of the project is to develop a potentially marketable system for clinical, epidemiological and translational research capable of associating contextual variables and geospatial data with clinical patient information. The GeoHealth system will include a section to perform exploratory analysis that will help identify risk factors to optimize clinical decision making. The system will be used in a study of the influence of environmental factors in more than 800,000 asthmatic patients in the region of Andalucía, Spain. The results of this study will help to develop predictive models of risk of exacerbation in asthma patients. Currently, disease management guidelines state that asthma control has two components: current disease control and future risk of exacerbations. These two components are key when assessing disease management, following a stepwise model that seeks to improve current control and minimize future risk. However, although the current control of the disease is defined and has established methodologies for its measurement (Asthma Control Test -ACT- and Asthma Control Questionnaire -ACQ-), the risk of suffering exacerbations is not yet a measurable component. Therefore, these predictive models could help in professional decision making for asthmatic patients. The predictive models will be validated prospectively and implemented in a decision support system for the management of asthmatic patients.

NCT ID: NCT05515276 Completed - Allergy Clinical Trials

The COVID-19 Pandemic Process Increase Latex Glove Use and Latex Allergy Complaints in Hospital Nurses? Survey Study

COVID19LATEX
Start date: June 1, 2021
Phase:
Study type: Observational [Patient Registry]

Background: Global guidelines recommend the use of personal protective equipment due to the high risk of contagiousness of COVID-19 disease. The increase in COVÄ°D-19 patients in the last two years has increased the rate of use of latex gloves in nurses. It is not known how the increase in the use of latex gloves affects the complaints of latex allergy in nurses. Aim: The aim of this study is to determine the rates of latex glove use and allergic complaints related to the use of latex gloves during the COVID-19 pandemic in hospital nurses.

NCT ID: NCT05487937 Completed - Allergy Clinical Trials

Toleriane Ultra Reno in Allergic Subjects With Skin Intolerance to Their Usual Cosmetic

Start date: May 25, 2021
Phase:
Study type: Observational

Sensitive skin is a subjective cutaneous hyper-reactivity to environmental factors. People report exaggerated reactions when their skin, especially on the face, is in contact with substances such as cosmetics. For this reason, Toleriane Ultra has been developed to limit the risk of allergy and relieve skin discomfort. The study aims at demonstrating that Toleriane Ultra is well tolerated in participants with allergic background and having experienced former intolerance to their cosmetic or toiletries routine, and improves skin sensitivity in such individuals. This open-labeled, multicenter study was conducted under dermatological control in Caucasian subjects above 16 years of age with an allergic background and intolerance to cosmetics lasting for at least 2 years prior to inclusion. The dermocosmetic product was to be applied on the entire face twice daily for 28 days.

NCT ID: NCT05476484 Active, not recruiting - Asthma Clinical Trials

Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma

Start date: April 1, 2022
Phase:
Study type: Observational

To assess the impact of SQ SLIT-tablets (SQ Grass SLIT-tablet and SQ HDM SLIT-tablet) in Danish and Swedish allergic rhinitis (AR) patients, with or without asthma, between 2007-2020.